A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19
Latest Information Update: 05 May 2021
At a glance
- Drugs Itolizumab (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections; Cytokine release syndrome
- Focus Adverse reactions
- Sponsors Biocon Biologic
- 29 Apr 2021 According to a Biocon media release, results of this study will be published soon.
- 29 Apr 2021 Status changed from recruiting to completed, according to a Biocon media release.
- 26 Nov 2020 New trial record